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Abstract
Chronic hepatitis B virus (HBV) infection adversely influ-
ences the clinical outcomes of renal transplant recipients 
owing to increased hepatic complications. Management 
of HBV infection in kidney transplant recipients presents 
a challenge to clinicians, especially in endemic regions. 
Interferon precipitates renal allograft dysfunction. Treat-
ment with lamivudine, the first oral nucleoside analogue 
available, resulted in effective viral suppression, re-
duced liver-related complications, and improved patient 
survival so that medium-term data showed compa-
rable patient survival rates between hepatitis B surface 
antigen-positive and HBsAg-negative kidney transplant 
recipients in the era of effective antiviral therapies. En-
tecavir has replaced lamivudine as first-line therapy for 
treatment-naïve subjects in view of the propensity for 
drug resistance with the latter. Management of HBV 
infection in kidney transplant patients needs to take 
into consideration the nephrotoxicity of nucleoside/tide 
analogues such as adefovir and tenofovir. Prevention of 
HBV-related complications in kidney transplant recipi-
ents starts much earlier prior to transplantation, with 
vaccination of patients with chronic kidney disease and 
donor-recipient matching with regard to HBV status. In 
addition to anti-viral treatment, patients with chronic 
HBV infection must have regular surveillance for liver 
cancer and assessment for the development of cirrhosis.
© 2014 Baishideng Publishing Group Co., Limited. All rights 
reserved.
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Core tip: Treatment with oral nucleoside/tide analogues 
brought a new paradigm in the management of hepa-
titis B surface antigen-positive kidney transplant recipi-
ents, resulting in effective viral suppression, reduced 
hepatic complications, and improved patient survival, 
without compromising renal allograft outcome. Ente-
cavir has replaced lamivudine as first-line therapy for 
treatment-naïve subjects given the propensity of lami-
vudine for selecting resistance. Due to the nephrotoxic-
ity of adefovir and tenofovir, the optimal management 
of drug-resistant hepatitis B virus (HBV) remains to be 
defined. Other important measures to prevent HBV-
related complications in renal transplant patients in-
clude early vaccination in non-immune subjects, donor-
recipient matching of HBV status, and surveillance for 
liver cancer and cirrhosis.
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INTRODUCTION
Hepatitis B virus (HBV) infection confers a significantly 
negative impact on the clinical outcomes of  kidney al-
lograft recipients. The inferior patient survival in hepatitis 
B surface antigen-positive (HBsAg+) renal transplant pa-
tients compared with the HBsAg-negative counterparts 
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is attributed to increased hepatic complications such 
as chronic hepatitis and cirrhosis, fibrosing cholestatic 
hepatitis, and hepatocellular carcinoma[1-10]. Prevention 
and management of  HBV infection in patients with 
renal failure is a major issue in endemic regions such as 
Asia, when the HBV carrier rate in the general popula-
tion can exceed 10%. The reported prevalence of  HBV 
infection among dialysis patients in the United States is 
often below 1.0%, whereas the prevalence rate is between 
7.0% and 15% in the Asian-Pacific region[11-13]. While the 
incidence of  HBV infection among dialysis patients has 
declined significantly over the past three decades because 
of  widespread implementation of  infection control mea-
sures, reduced need for transfusion and adherence to safe 
transfusion practices, and the introduction of  HBV vac-
cination to neonates in many countries, over 350 million 
subjects worldwide carry HBV and thus it will remain a 
significant clinical issue for some time[14]. In this context, 
a considerable number of  HBsAg-positive patients will 
undergo kidney transplantation[15].
PREVENTION OF DE NOVO HBV 
INFECTION IN RENAL TRANSPLANT 
RECIPIENTS
An effective immunization program in dialysis and 
chronic kidney disease patients is the cornerstone to 
prevent de novo HBV infection in renal transplant recipi-
ents. HBV vaccination should be given early in the course 
of  chronic kidney disease owing to the relatively poor 
response in patients with significant renal impairment[16]. 
In the dialysis population, higher doses of  vaccine are 
recommended, with post-vaccination and subsequent an-
nual testing and booster administration if  anti-HBs titer 
falls below 10 IU/L[17]. Intra-dermal injection may be 
considered in non-responders to enhance the vaccination 
efficacy[18]. The donor-recipient matching with regard to 
their HBV serological status significantly affects the risk 
of  de novo HBV infection post-transplant. One must not 
transplant an HBsAg-positive allograft into a recipient 
who is negative for both HBsAg and anti-HBs, or de 
novo infection would occur and the course is often ag-
gressive[19]. The risk of  HBV transmission from HBsAg-
negative anti-HBc positive donors to HBsAg-negative 
recipients is low, and the risk is even lower if  the recipient 
is anti-HBs positive[20]. Accumulating experience suggests 
that it is safe to transplant an HBsAg-positive kidney to 
an HBsAg-negative recipient who has anti-HBs antibody 
under HBV immunoglobulin cover[21].
CLINICAL OUTCOMES OF HBSAG-
POSITIVE RENAL TRANSPLANT 
RECIPIENTS IN THE PRE-ANTIVIRAL 
NUCLEOSIDE/TIDE ANALOGUE ERA
The clinical manifestations and diagnosis of  HBV infec-
tion in kidney transplant recipients are generally similar 
to patients without renal disease, but due to the immu-
nosuppressed state these individuals are more susceptible 
to progressive liver disease and severe life-threatening 
complications like fibrosing cholestatic hepatitis[10]. The 
significantly inferior survival of  HBsAg-positive kidney 
transplant recipients in the “no-treatment” era was re-
garded unavoidable, and much of  the mortality occurred 
relatively early, due to severe progressive liver disease[2-7,9]. 
In a meta-analysis of  six observational studies, HBsAg-
positivity was associated with a 2.49-fold risk of  death 
after renal transplantation[22]. Liver-related complications 
were significantly increased in subjects with detectable se-
rum HBV DNA or were HBeAg-positive[23]. The 10-and 
20-year patient survival rates in HBsAg-positive kidney 
transplant recipients without anti-viral therapy were 85% 
and 71% respectively (vs 98% and 95% at 10 and 20 years 
in HBsAg-negative patients)[24].
Before the availability of  oral nucleoside/tide ana-
logues, chronic HBV infection was managed with inter-
feron therapy. Interferons offer the advantage of  sus-
tained response with a finite duration of  therapy in both 
HBeAg-positive and HBeAg-negative patients[25]. How-
ever, there has been data suggesting that the efficacy of  
interferon might be lower in endemic regions where most 
patients contract the infection during infancy, compared 
to non-endemic areas where the infection is contracted 
during adulthood[26,27]. Moreover, interferon should be 
avoided in kidney allograft recipients as it commonly pre-
cipitates allograft dysfunction and rejection[28,29], although 
one study suggested that interferon treatment might not 
be associated with acute rejection in HCV-positive kidney 
transplant recipients with low rejection risk[30]. With the 
advent of  oral nucleoside/tide analogues which sup-
press HBV replication effectively, there was a dramatic 
change in the clinical course of  HBsAg-positive kidney 
transplant recipients and a new paradigm of  therapeutic 
management.
IMPACT OF NUCLEOSIDE/TIDE 
ANALOGUE THERAPY ON THE 
OUTCOMES OF HBSAG-POSITIVE RENAL 
TRANSPLANT RECIPIENTS
The current options of  nucleoside/tide analogues include 
lamivudine, entecavir, telbivudine, adefovir and tenofovir 
(Table 1). The objective of  treatment is to prevent HBV-
related complications in these immunosuppressed indi-
viduals, and the indication to start treatment is based on 
the commencement of  immunosuppressive therapy (the 
“prophylactic” approach) or the evidence of  impending 
HBV reactivation (the “pre-emptive” approach). Due 
to a paucity of  data, the optimal duration of  antiviral 
treatmentin HBsAg-positive kidney transplant recipients 
remains undefined. Preliminary experience suggests that 
while most patients would require lifelong anti-viral sup-
pression discontinuation may be cautiously attempted 
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after stabilization, with success, in carefully selected low-
risk patients[1].
Lamivudine
Since lamivudine is the first amongst this class of  drugs 
available for clinical use, it has yielded the majority of  
data on the management of  HBsAg-positive renal trans-
plant recipients. Lamivudine given as either prophylactic 
or pre-emptive treatment was proven superior to salvage 
therapy when liver dysfunction is evident[11,31]. Data from 
our group and other investigators have demonstrated that 
lamivudine was effective in suppressing HBV DNA and 
improving liver transaminase levels[1,22,32]. A meta-analysis 
which pooled data from 14 prospective clinical trials (a 
total of  184 patients) supported these observations[33]. 
With lamivudine as initial treatment, the mean rate of  
effective HBV DNA suppression, HBeAg clearance, ala-
nine transaminase (ALT) normalization, and lamivudine-
resistance was 91% (95%CI: 86%-96%), 27% (95%CI: 
16%-39%), 81% (95%CI: 70%-92%), and 18% (95%CI: 
10%-37%) respectively after a mean duration of  14 mo. 
The frequency of  HBeAg seroconversion and lamivudine 
resistance correlated positively with treatment duration. 
Most importantly, treatment with lamivudine was associ-
ated with significantly improved patient survival[1,10,24]. 
With the use of  lamivudine, the 10-year patient survival 
rate in HBsAg-positive renal transplant recipients was 
81% and such results were nearly comparable to HBsAg-
negative patients[24]. Although antiviral treatment has led 
to reduced mortality as a result of  decreased hepatic com-
plications (P = 0.036), liver-related deaths still accounted 
for 40% of  mortalities in HBsAg-positive patients in 
the era of  effective antiviral therapies, and 22.2% of  all 
deaths that occurred in patients who had received anti-
viral treatment[24]. Prolonged treatment with lamivudine 
is associated with progressive increase in drug resistance 
and the cumulative probability of  developing lamivudine-
resistance was approximately 60% after 69 mo[24,33-35]. The 
emergence of  lamivudine resistance can be associated 
with liver dysfunction, although one recent study showed 
that drug resistance did not have a significant negative 
impact on liver stiffness score, rate of  HBeAg serocon-
version rate, incidence of  liver failure or hepatocellular 
carcinoma, or patient survival over 10-14 years of  follow-
up when rescue antiviral therapies are available[24].
Adefovir
Adefovir has similar activity against both wild-type and 
lamivudine-resistant HBV, this drug is nephrotoxic and 
the major clinical application of  this antiviral agent is for 
the management of  lamivudine-resistance[36]. Data re-
garding the management of  lamivudine-resistance in kid-
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Table 1  The major clinical trials regarding the use of oral nucleoside/tides for HBsAg-positive kidney transplant recipients
Oral Nucleoside/tides Study design n Major treatment outcomes
Lamivudine
   Rostaing et al[32] (1997) Prospective   6 LAM as initial Rx → ALT normalization and HBV DNA undetectability in 4/6 patients
   Chan et al[1] (2002) Prospective 11 LAM as initial Rx → ALT normalization and HBV DNA undetectability in all patients; 
e-seroconversionrate (21.4%); markedly improved patient survival when compared to historical controls 
who had no anti-viral Rx (P < 0.001)
   Fabrizi et al[33] (2004) Meta-analysis 184 LAM as initial Rx → HBV-DNA undetectability [91% (95%CI: 86%-96%)], ALT normalization [81% 
(95%CI: 70%-92%)] and LAM-resistance [18% (95%CI: 10%-37%)] after 12 mo; e-seroconversion rate 
(0%-46%) in 4 trials
   Thabut et al[34] (2004) Prospective 14 LAM as initial Rx → HBV undetectability (57%) andALT normalization (57%) after 3 mo; LAM-resistance 
(57%) after median of 15 mo
   Filik et al[31] (2006) Prospective 15 LAM as initial Rx → HBV DNA undetectability (46.7%) after 2 yr
   Yap et al[24] (2010) Retrospective 38 LAM as initial Rx → LAM-resistance (64%) after 4 yr; improved long-term patient survival (83% vs 34% 
at 20-yr, P = 0.006) when compared to historical controls who had no anti-viral Rx
Adefovir
   Fontaine et al[37] (2005) Prospective 11 ADV as mono-therapy for LAM-resistant KTR → 5 log ↓ HBV DNA after 1 yr, only 1 patient had 
transient deterioration of allograft function
   Kamar et al[40] (2009) Prospective 11 ADV for LAM-resistant KTR → significant ↓ in HBV DNA (P = 0.01) and ALT normalization after 12 mo, 
↑serum creatinine and proteinuria after 24 mo (P = 0.02)
   Tse et al[43] (2010) Retrospective 4 ADV for LAM-resistant KTR → 4 log ↓ HBV DNA and significant ↓ ALT levels (P = 0.029) after 18 mo, 
no significant change in allograft function
   Lampertico et al[41] (2011) Prospective 11 ADV as add-on Rx to LAM for LAM-resistant KTR → HBV undetectability (88%) after 3 yr; no significant 
changes in renal function and proteinuria
   Lai et al[42] (2012) Retrospective 14 ADV as mono- (n = 5) or add-on (n = 9) therapy in LAM-resistant KTR → HBV DNA undetectability [5 
(35.7%) and 6 (42.8%) patients]after 12 and 24 mo with no virological breakthrough; ALT normalization 
in 13 patients (92.8%) after 1 yr; moderate to severe renal insufficiency (29%)
Entecavir
   Kamar et al[48] (2008) Prospective 10 ETV for ADV-resistant (n = 9) or LAM-resistant (n = 1) KTR → HBV DNA undetectability (50%) after 
16.5 mo
   Hu et al[47] (2012) Prospective 27 ETV in KTR patients without LAM-resistance → HBV DNA undetectability (96% and 100%) after 12 and 
24 mo, with no virological breakthrough
Tenofovir
   Daudé et al[52] (2011) Prospective   3 TFV as mono-therapy → HBV DNA undetectability (43%); no changes in allograft function
ADV: Adefovir; ALT: Alanine transaminase; ETV: Entecavir; LAM: Lamivudine; KTR: Kidney transplant recipients; TFV: Tenofovir; HBV: Hepatitis B virus. 
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evidence of  worsening of  renal allograft function during 
follow-up[24]. However, one must appreciate that the an-
tiviral activity of  adefovir at the currently approved dose 
is relatively weak, and efficacy could be further reduced 
with dose adjustment according to renal dysfunction.
Entecavir, tenofovir and telbivudine
Entecavir is effective in both treatment-naïve and lamivu-
dine-resistant patients[44,45]. In immunosuppressed treat-
ment-naïve post-renal transplant patients who required 
prolonged antiviral administration, entecavir is preferred 
due to its high resistance barrier and favorable safety pro-
file[44,46]. A recent 2-year prospective study showed that 
the use of  entecavir in treatment-naïve renal transplant 
recipients resulted in undetectable HBV DNA levels in 
70%, 74%, 96% and 100% of  patients after 12, 24, 52 
and 104 wk respectively[47]. In this study, entecavir was 
associated with a more potent response than lamivudine 
and the tolerability profile was favorable. Experience re-
garding the use of  entecavir in renal transplant recipients 
who had developed lamivudine- or adefovir-resistance 
had been examined in a small study with 10 solid organ 
transplant recipients (8 kidney allograft recipients)[48]. 
Treatment with entecavir resulted in an appreciable drop 
in HBV DNA levels and a 50% HBV undetectability in 
both HBeAg-positive and HBeAg-negative patients af-
ter 16.5 mo of  therapy. Previously we had also reported 
the efficacy and tolerability of  entecavir in lamivudine-
resistant kidney allograft recipients, and showed that 
the virological response could be variable and relatively 
slower compared with treatment-naïve subjects[24,43]. Thus 
ney transplant recipients is relatively limited[37-39]. Prior to 
the availability of  alternative nucleoside/tide analogues, it 
was the usual practice to continue lamivudine in patients 
who had developed lamivudine-resistance. Since the in-
troduction of  adefovir, there have been reports on its 
short-term efficacy either as mono- or add-on therapy in 
kidney transplant recipients[37-42]. The study by Fontaine et 
al[37] examined the use of  adefovir as monotherapy in 11 
post-kidney transplant patients with dosage adjustment 
according to renal function. Adefovir treatment led to a 
significant decline in serum HBV DNA with no virologi-
cal breakthrough at one year and the drug was well-toler-
ated. Others have reported that adefovir as add-on ther-
apy to lamivudine resulted in undetectable HBV DNA 
levels in 35.7%, 42.8% and 88.0% of  lamivudine-resistant 
renal transplant recipients after 12, 24 and 36 mo[41,42]. 
There was no virological breakthrough and normalization 
of  ALT was achieved in 92.8% of  patients after 12 mo 
of  treatment[42]. However, the virological response could 
be variable and relatively slow when compared with treat-
ment-naïve subjects[43]. Nevertheless, rescue therapy with 
adefovir resulted in significantly better viral suppression 
and liver biochemistry compared with continuation of  
lamivudine (75% vs 14.3% had persistent normalization 
of  ALT), and the clinical response was sustained for at 
least 24 mo[24]. Evidence of  nephrotoxicity was observed 
in 30%-50% of  renal allograft recipients despite dosage 
adjustment, and could necessitate treatment discontinu-
ation[41,42]. In our experience, using adefovir in patients 
with serum creatinine below 150 μmol/L or creatinine 
clearances above 40 mL/min appeared safe, without 
All RRT patients
Check HBsAg, Anti-HBc and Anti-HBs
If HBsAg-ve and anti-HBs-ve: HBV vaccination
HBsAg+ donor → HBsAg- recipient HBsAg+ recipient
Only when recipient is anti-HBs+ve
Pre-operative HBIG
Anti-viral Rx to donor and recipient if 
donor HBV DNA+ or HBeAg+
Repeat HBV serology after 
transplantation
Treatment-naive Already on LAM/ETV 
Prophylactic OR Pre-emptive 
approach
 
ETV as first line therapy
Monitor LFT/HBV DNA/ AFP/USG
For virological breakthrough or genotypic resistance:
Consider switch to ADV/TFV
Monitor allograft function
Figure 1  Management algorithm of hepatitis B virus infection in renal transplant recipients. ADV: Adefovir; AFP: Alpha-fetoprotein; ETV: Entecavir; HBIG: 
Hepatitis B hyperimmune globulin; HBV: Hepatitis B virus; HBsAg: Hepatitis B surface antigen; LAM: Lamivudine; LFT: Liver function test; RRT: Renal replacement 
therapy; TFV: Tenofovir; USG: Ultrasonography. 
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the response to entecavir in lamivudine-resistant subjects, 
and the subsequent emergence of  entecavir-resistance, 
should be carefully monitored[49].
Tenofovir shows high efficacy in the treatment of  
treatment-naïve or lamivudine-resistant HBV infec-
tion[45,50]. There is little data in the renal transplant setting, 
and there is concern on its potential nephrotoxicity[51]. 
Daudé et al[52] reported the favorable short-term virologi-
cal response and renal function stability in 7 solid organ 
transplant recipients (3 kidney allograft recipients) with a 
follow-up of  12 mo. Larger studies with longer follow-up 
duration are warranted to ascertain the long-term efficacy 
and effect on kidney allograft function. There is currently 
no data on the use of  telbivudine in renal transplant re-
cipients but it would be worthwhile to explore the use of  
this agent in treatment-naïve kidney allograft recipients 
given its relatively low resistance rate, lack of  nephrotox-
icity, and the relatively lower cost compared with other 
nucleoside/tide analogues[53,54].
CONCLUSION
The outcome and management of  HBsAg-positive 
kidney transplant recipients have changed dramatically 
over the past few decades (Figure 1). Prior to the advent 
of  effective and safe therapy, HBV infection had such 
a severe negative impact on patient survival that some 
centres regarded HBsAg sero-positivity as a contraindica-
tion against kidney transplantation. In the era of  effective 
nucleoside/tide analogue therapy the 8-10 year survival 
rate of  HBsAg-positive kidney transplant recipients is ap-
proaching that of  HBsAg-negative subjects. The access 
to optimal therapy is limited by the cost of  drugs in some 
places, unfortunately often in endemic regions when the 
treatment is needed most. The management of  patients 
with drug resistant HBV infection remains a challenge, 
as is the nephrotoxic impact of  some effective anti-viral 
agents. Apart from the treatment of  HBV infection with 
anti-viral agents, the importance of  regular surveillance 
for liver complications cannot be over-emphasized. In 
this regard, the data clearly shows that early detection of  
liver tumour with ultrasound and alpha-fetoprotein level 
measurement markedly increases the resection rate and 
patient survival[55-57].
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